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Abstract
Low protein levels and copy number variation (CNV) of the fourth component of human complement (C4A and C4B) have
been associated with various diseases. High-throughput methods for analysing C4 CNV are available, but they commonly do
not detect the most common C4A mutation, a silencing CT insertion (CTins) leading to low protein levels. We developed a
SYBRH Green labelled real-time quantitative polymerase chain reaction (qPCR) with a novel concentration range approach
to address C4 CNV and deficiencies due to CTins. This method was validated in three sample sets and applied to over 1600
patient samples. CTins caused C4A deficiency in more than 70% (76/105) of the carriers. Twenty per cent (76/381) of patients
with a C4A deficiency would have been erroneously recorded as having none, if the CTins had not been assessed. C4A
deficiency was more common in patients than a healthy reference population, (OR=1.60, 95%CI=1.02–2.52, p=0.039). The
number of functional C4 genes can be straightforwardly analyzed by real-time qPCR, also with SYBRH Green labelling.
Determination of CTins increases the frequency of C4A deficiency and thus helps to elucidate the genotypic versus
phenotypic disease associations.
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Introduction
Deficiencies of complement component C4 isotypes, C4A
(MIM+120810) and C4B (MIM *120820), have been associated
withvariousautoimmune,inflammatoryorinfectiousdiseasesaswell
as with mental disorders and cancer survival [1–4]. Phenotypic C4
deficiencies are caused by increased protein consumption or genetic
deficiencies,which may,inturn,resultfrom deletions,conversionsor
silencing mutations [5,6]. Low copy number variation (CNV, less
than 2 copies)causespart, but not allphenotypic C4deficiencies as it
detects deletions and conversions, but not the silencing mutations
[7]. The most common mutation leading to C4A silencing is a two-
nucleotide CT-insertion (CTins MIM+120810) in exon 29, codon
1213 and is virtually absent in C4B [8,9].
Real-time quantitative polymerase chain reaction (qPCR)
measures the amount of PCR products. It has been named as the
‘‘method ofchoice’’forCNVanalysesinspiteofthe limitations[10–
12]. The current real-time qPCR methods for C4 CNV determi-
nation use the TaqManH probing [13–15]. The presence of CTins
has not been assessed with qPCR before [16–19].
In this study we describe and validate a sensitive and specific,
low-cost real-time qPCR assay with SYBRH Green labelling for
absolute quantification of CNV of C4A, C4B and CTins analyses. It
has been successfully applied in parallel with C4 immunopheno-
typing to more than 1600 patient samples.
Materials and Methods
Samples
Internal validation. Seven cases were collected from sam-
ples sent to our Laboratory. They were selected to cover the most
common C4A and C4B CNVs, the presence of CTins and different
genetic backgrounds of C4A deficiency (low CNV [samples 1586
and 2209] or silencing by CTins [samples 2144 and 2158],
Figure 1A and B, Supplementary Table S1).
External validation. Samples with published C4 CNVs were
analysed to see whether qPCR results are applicable for samples
processed by different DNA isolation methods. This was done in
two different sample cohorts. Genomic DNA from 48 cell lines of
consanguineous subjects with previously published C4 CNV by
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38813
2real-time qPCR with TaqManH dye [14] were purchased from the
International Histocompatibility Working Group (IHWG) Cell
Bank (Seattle, WA). Two samples (IHW09038 and 09102) were
not available. Six samples with the most common C4A and C4B
CNVs were used for method validation (Supplementary Table
S2). Eighty-nine HapMap samples had been previously genotyped
in parallel with three different methods, our SYBRH Green real-
time qPCR, southern blotting and paralog ratio test [20].
Diagnostic routine. Between November 2004 and Decem-
ber 2009, 1648 samples of serum (2 ml) and peripheral EDTA
blood (7 ml) were received in our accredited diagnostic HLA
Laboratory for parallel qPCR CNV and immunophenotype
analysis of C4A and C4B. These samples were considered to
represent mainly infection prone (based on clinicians’ suspicion)
patients as 60% of the samples were sent from the Division of
Infectious Diseases in Helsinki University Central Hospital using
such indications (personal communication, A. Ja ¨rvinen).
The Ethics Committee, Department of Medicine, Hospital
District of Helsinki and Uusimaa, waived the need for committee’s
approval and patient consent because the used patient material
was retrospectively and anonymously analysed as frequency data
from our Diagnostic Laboratory’s result without patient identifi-
cation, any interventions or contacts due to the current study. The
results were commanded on clinical grounds from different
institutions and used to guide patient care as seen suitable by
the treating clinician.
Sample Preparation
DNA was extracted from the buffy coat fraction of whole blood
by NucleoSpin QuickPure columns (Machery-Nagel, Duren,
Germany), diluted to 50 ng/ml in sterile water, and, after assessing
purity (A260/A280.1.7), adjusted to 10 ng/ml (between 8.0 and
14.0 ng/ml) by spectrophotometer (NanoDropH ND-1000, Nano-
Drop Technologies, Wilmington, DE, precision 0.1 ng/ml) for
further use. Once diluted, the samples had to be stored at +8C
and analysed within 2–3 weeks. The purchased samples were
extracted as described elsewhere, otherwise handled as above
(http://locus.umdnj.edu/nigms/) [14].
Primers and Master Mixes
The primers (Sigma Genosys, Heverhill, UK) were selected
based on published sequences, allowing distinction between C4A
and C4B on four of their five-base pair differences on exon 26 and
detection of CTins in exon 29 (Table 1) [8,9,21,22]. The primer
and amplicon lengths, end specificity, G/C-contents, absence of
secondary structures and Tm differences were optimized
(Table 1).
Two SYBRH Green Master Mixes (ABsolute
TM qPCR SYBRH
Green Mix, AB-1159, ABgene, Epsom, UK and Brilliant SYBRH
Green QPRC Master Mix, Staratagene, AH Diagnostics, Ska ¨rhol-
men, Sweden) with modified Taq polymerase having hot start
capability were used depending on the analysis (Table 1).
PCR Program
Real-time qPCR was performed with Rotor-Gene 3000
(Qiagen, Vienna, Austria). Reactions were adjusted to a final
volume of 10 ml/well using 2 ml of genomic DNA (10 ng/ml),
0.25 ml of both of primers (20 pmol/ml), 2.5 ml of sterile water and
5 ml of Master Mix.
Figure 1. Method validation with selected samples. A. Immu-
nophenotyping. The gel is skewed in the middle, leading to lower
position of protein band levels on the left. All samples were analysed in
a replicate run. B. Real-time quantitative PCR (qPCR) for copy number
variation. The y-axis depicts the linear view of the fluorescence rate
(from 0 to 0.6 in the full picture, from 0 to 0.06 in the magnification) and
the x-axis the number of cycles (from 0 to 30 in the full picture and 15
to 21 in the magnification). Each curve represents the mean of two
replicates of a sample. The lowest horizontal line represents non-
template controls (sterile water), negative control and samples with
zero copies of C4B having zero fluorescence due to undetectable
amounts of DNA (TX-2144 and TX-2147). The curves from left to right
depict samples with C4B CNV 3, 2 and 1 (TX-1586, TX-2170 and TX-2158,
TX-2209 and TX-2284, respectively). The number of cycles at which the
fluorescence curve cuts the threshold (the red horizontal line) is
recorded; the greater amount of genes indicates the lower number of
cycles surpassing the threshold. C4A and CTins qPCR runs resulted in
similar output. C. Parallel results of C4 analyses. Functional C4A CNV
was assessed by reducing the amount of CTins from C4A CNV.
doi:10.1371/journal.pone.0038813.g001
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minutes, followed by 30 three-step cycles (15 seconds at +95uC, 45
seconds at annealing temperature and 45 seconds at +72uC). The
annealing temperatures are indicated in Table 1.
Samples with known C4 CNV (from 0 to 3 in C4A and C4B runs
and from 0 to 1 in CTins run, patient samples with consistent
immunophenotyping and qPCR results) served as controls. It is
extremely rare to have two copies of CTins and therefore a control
with two copies was used in a replication run when needed.
Specificity Assessment
Other sequences were not specifically found, when performing
the BLAST-search (www.ncbi.nih.gov/BLAST). Using the Prim-
er-BLAST option, the mismatched primers did not produce
similar sized amplicons.
A melt analysis (ramping from +65uCt o+95uC, rising the
temperature by 0.2uC at every step with 2-seconds interval),
performed after the CNV runs, exhibited only one peak
characterizing a homologous amplicon in C4A and C4B runs.
For CTins, two individual non-overlapping peaks were detected,
but the samples with the nonspecific peak at lower temperature did
not surpass the threshold Ct in the actual qPCR run (data not
shown).
Data Analysis
Raw data were analysed using Rotor-Gene software v 6.0
(Qiagen, Vienna, Austria). Prior to the C4 CNV analyses, the
DNA concentration comparability between samples and controls
was assured by the amplification of a housekeeping gene (beta-
actin) in parallel with standard dilutions of 8, 10 and 14 ng/ml.
Samples outside this range were discarded. The sample’s
concentration was categorized as comparable (9–11 ng/ml,
assuming control concentration 10 ng/ml), lower or higher than
the control’s concentration. The use of concentration range was
used to prevent the false interpretation of CNVs (Supplemen-
tary Table S3).
The run validity can be estimated by R
2-value and reaction
efficiency. The R
2-value is used to depict how well the standard
curve can be drawn from the given data. Reaction efficiency
(percentage) can be assessed from standard curve.
Run validity was ensured by controls and adequate standard
curves (R
2.0.8). Outlier Ct-values resulting from nonspecific
amplification were excluded.
The primary fluorescence data was normalized according to the
Manufacturer’s instructions. Briefly, the first ten cycles were
ignored and the background fluorescence was adjusted using
Dynamic Tube Normalization-option. The threshold level of
fluorescence was set to separate different CNVs by one Ct
(Table 1).
The determination of CNV was performed by visual inspection,
superimposing the sample’s trace on the controls’ traces. Samples
with comparable concentration with the controls were recorded
having the CNV of the closest trace (Ct difference ,0.4). Samples
with lower or higher concentration than the controls were rounded
up or down, respectively. Samples with lower concentration and
Ct values between 2 and 3 were rounded up to CNV 3. With
higher concentrations, the values were rounded down to CNV 2.
The same logic applies to other CNVs. High CNV numbers (4 or
5) with higher concentration than the controls were re-diluted
(Supplementary Table S3). Samples with unclear CNVs were
either re-assessed in beta-actin run with the controls or re-diluted
from the stock.
The analysis program calculates CNVs by inserting the Ct-value
into the standard curve equation and is used as a second opinion.
Briefly, a linear standard curve equation is formed from controls’
Ct-values (cycle threshold, the number of cycles at which the
sample’s trace exceeds an arbitrary threshold, values .26
considered as outliers) and logarithmic transformation of given
concentration (with beta-actin analyse) or CNV (with C4 analyses).
The unknown sample’s DNA quantity is calculated from the
equation of standard curve with the obtained Ct value. CTins was
reduced from the total C4A CNV.
C4 Immunophenotyping
C4 immunophenotyping of diagnostic samples was carried out
from serum as described (Figure 1) [23,24]. One specialist (M-
L.L.) analyzed all data independently of the genotyping results.
The number of C4 genes was estimated from protein bands and
subsequently compared with the qPCR results in order to
differentiate between the primary and secondary complement
C4 deficiencies in a semi-quantitative fashion.
Table 1. Primer sequences of C4A, C4B, CTins and Beta-actin qPCR runs.
qPCR Primer Specificity Sequence 59–39
a
SYBRH
Green Mix
Annealing
temperature
(6C)
Amplicon
size (bp)
Analysis
threshold Reference
C4A C4A_F C4A AGG ACC CCT GTC CAG TGTT A G AC ABsolute
TM 55 247 0.03 [22]
C4A/B_R C4 CAC TCT CTG CTT CAA TGG CT [22]
C4B C4B_F C4B AGG ACC TCT CTC CAG TGAT A C A BrilliantH 57 247 0.03 [22]
C4A/B_R C4 CAC TCT CTG CTT CAA TGG CT [22]
CTins C4INS_ F CTins CTC TTC TCC CTG CCT TCC T BrilliantH 57 88 0.1 [21]
C4INS_ R CTins GCT CTG AGA ACC AGT GAC TGA GAG [8,9,21]
Beta-actin ACTIN_F Beta-actin GCA CTC TTC CAG CCT TCC ABsolute
TM 60 435 0.05
ACTIN_R Beta-actin GCG CTC AGG AGG AGC AAT
Abbreviations:
qPCR (real-time quantitative polymerase chain reaction),
CTins (CT-insertion mutation of C4A leading to non-expression).
aSpecific bases are underlined.
doi:10.1371/journal.pone.0038813.t001
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Statistical analyses were performed using PASW Statistics,
version 18.0. Chi-square test with two-sided exact p-value was
used at significance level ,0.05. Cohen’s Kappa was calculated
for C4 CNV values in methodologically satisfactory results in both
geno- and phenotypic analyses (n=1500 for C4A and n=1542 for
C4B). C4 CNV frequencies were compared with reference
population including samples with methodologically satisfactory
result in all qPCR analyses (n=1618).
Results
Internal Validation Shows No Overlap in Samples with
Different Copy Numbers
The internal validation was performed with samples selected
amongst diagnostic patients as the real-time qPCR optimization
was performed with similarly processed samples (Figure 1). The
qPCR analyses were replicated from two different dilutions, in five
independent runs.
CNVs of a gene were consistently segregated by approximately
one cycle in all replications. The inter-run and -dilution variance
was very small (Table S1). Grouping all samples with a given
CNV did not reveal any overlap in 95% confidence interval of Ct-
values, even though different dilutions were combined (Table 2).
The variance seemed to grow with increasing copy numbers,
possibly due to greater sensitivity in sample manipulation in
elevated concentrations. However, only C4B analysis showed
increased variance in high CNVs, when samples were individually
assessed (Table S1).
For run validity analyses, samples were assessed as controls with
known CNVs for R
2 and reaction efficiency determinations. The
mean R
2 values and reaction efficiencies were 0.88, 87.7% and
0.90, 115% for C4A and C4B runs, respectively (Table S1). For
CTins runs these values were essentially similar (data not shown).
Intercept values did not significantly differ between different runs
(data not shown).
Real-time qPCR is Applicable also to External Samples,
but Controls have to be Isolated Using Similar Protocols
to Ensure Reliable Results
In housekeeping gene analysis, the external samples were not
comparable with our control samples, making the absolute
quantification demanding (data not shown).
The six IHWG samples for validation were replicated from two
dilutions, in eight separate analyses. The samples with different
CNVs were seen to differ by one cycle with no overlap between
different CNVs and total consistency with published C4 CNV
(Table S2). The Ct-values of a given CNV were close, but not
comparable with the diagnostic samples’ values.
The C4 CNV of the remaining 41/42 samples were concordant
with previous results (98%, data not shown) [14]. The sample
IHW09023 was reported to have zero copies of C4A. In our
analyses, however, the CNV was repeatedly two. None of the
studied samples carried CTins.
Of the 89 HapMap samples, 8 having consistent results in
paralog ratio test and Southern blotting had discrepant results in
real-time qPCR assay (data not shown) [20]. The samples might
be degraded as the quality (A260/A280,1.7 n=7) or concentra-
tion (beta-actin below the control dilutions n=1) was inadequate,
and as the discrepancies were all due to lower detected CNV by
PCR. Retyping these samples by adjusting the concentration by
approximation resulted in concordant results in 7/8 samples.
Real-time qPCR and Immunophenotyping Exhibit Great
Compatibility in Patient Samples
C4A and C4B CNV, CTins and serum C4A and C4B protein
phenotypes were independently analyzed from 1648 patients.
For C4A, the results were unambiguous in 98.4% (1621/1648)
for qPCR and in 92.4% (1523/1648) for immunophenotyping of
the samples. For C4B, the corresponding numbers were 99.7%
(1643/1648) and 93.8% (1545/1648), respectively. Ambiguous
immunophenotyping was seen in samples that were homogenous
regarding either C4A or C4B, as expected.
In samples with unambiguous results in both analyses, the copy
numbers showed concordance in 95.7% for C4A (1436/1500,
Table 2. Results of samples in method validation, detailed by copy numbers.
Copy number
a (n) Replications (n) Mean Ct value 95%CI SD Range Variance (%)
C4A 0 12
b
1 52 21.36 21.3–21.41 0.19 0.79 4
2 52 20.4 20.33–20.46 0.24 1.21 6
3 52 19.58 19.47–19.69 0.4 1.42 16
C4B 0 26
1 26 21.06 20.95–21.17 0.28 1.2 8
2 52 20.25 20.17–20.33 0.28 1.14 8
3 52 19.63 19.52–19.73 0.39 1.64 15
CTins 0
1 72 24.46 24.36–24.56 0.41 2.39 17
Abbreviations:
Ct (cycle threshold value, the number of cycles needed to surpass a threshold value, that is inversely related to the copy number of genes),
CI (confidence interval),
SD (standard deviation),
C4A, C4B (complement components C4A and B),
CTins (CT-insertion mutation of C4A leading to non-expression).
aFor detailed results on individual samples, concentrations and runs, see Table S1.
bFourteen Ct values .26 were discarded as outliers.
doi:10.1371/journal.pone.0038813.t002
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1542, kappa=0.95, p,0.001). The discrepancies were mainly
cases with lower protein levels (85.9%, 55/64 for C4A and 81.4%,
35/43 for C4B, Table S4A and B). Both C4A and C4B copy
numbers were divergent in 28 patients. Twenty-three of them had
lower serum C4 levels than expected by genetic background.
Eleven subjects had no detectable C4A protein regardless the
presence of C4A genes (Table S4A. For C4B, the corresponding
number was twelve. These may represent subjects with increased
consumption, lowered production or uncharacterized mutations.
Complement C4 Gene Frequencies in Infection Prone
Patients Differ from General Population
The frequencies of C4A, C4B and CTins are shown in parallel
with published frequencies in different populations in Table S5.
The most common C4 CNV was two for both C4A and C4B,
detected in more than half of the cases. CTins was present in 6.4%
(105/1618) and resulted in C4A deficiency (functional CNV ,2) in
72% (76/105) of carriers.
Low C4A CNV (,2) was recorded in 18.9% (305/1618),
whereas phenotypic C4A deficiency (low functional CNV caused
by low CNV and CTins) in 23.5% of study samples (381/1618)
(Figure 2). Twenty per cents (76/381) of phenotypic C4A
deficiency were due the presence of non-expression caused by
CTins. Both forms of C4A deficiency were more frequent in
patients than in a population sample of same nationality, although
the low CNV seemed to cause a larger difference (OR=1.93 95%
CI=1.13–3.29, p=0.014 for low CNV and OR=1.60,
95%CI=1.02–2.52, p=0.039 for phenotypic C4A deficiency,
Figure 2). C4B deficiency was more frequent in patients, but the
difference did not reach statistical significance.
When C4A and C4B combinations were constructed, the
patients had significantly lower frequency of two copies of C4A
without CTins and two copies of C4B, the most common
combination of healthy subjects of same nationality (29% vs.
39%, respectively; p=0.017, data not shown). C4 CNVs of
different isotypes were inversely correlated, (high C4A CNV was
associated with low C4B and vice versa, data not shown) as
previously stated. [19].
Allotype (Allele) Frequencies do not Differ in Study
Populations
Allotype frequencies were calculated from samples with
concordant qPCR and immunophenotyping (Table S6). The
allele distribution was essentially similar to that of a population
sample of same nationality (data not shown).
Discussion
We have developed a simple and reliable real-time qPCR assay
for determining the complement C4A, CTins and C4B copy
numbers. Combining the C4A and CTins results enables the
assessment of different forms of C4A deficiencies and -related
disease associations. This approach also allows the distinction
between phenotypic and genotypic disease associations. The
results are comparable with different methods, even with DNA
isolated by different protocols [20].
SYBRH Green emits strong fluorescence on excitation when
binding double stranded DNA. The amount of DNA is directly
proportional to the fluorescence. Compared to TaqManH, the
SYBRH Green labelling is inexpensive, has the capability to be
used with all real-time cyclers and bears a smaller risk of obtaining
inconclusive results (2% vs. 5%) and is therefore an appealing
choice for a diagnostic tool [14,25]. We have used this method in
disease association studies and also in assessing HLA-alleles [26–
28].
Absolute quantification allows the direct determination of CNV.
The use of many controls decreases the error rate [10,14]. The use
of concentration range allows reliable results with both compara-
ble and slightly different concentrations without the need of
Figure 2. Frequencies of C4 deficiencies in different populations. The frequencies (%) of phenotypic C4A deficiency (functional C4 copy
number ,2, CTins reduced from C4A), C4A deficiency (copy number ,2) and C4B deficiency (copy number ,2) are shown. The populations are
Finnish patients from the current study with unambiguous C4 qPCR results (n=1618), Finnish (n=149) [28], Hungarian (n=118) [13], U.K. (n=719) [9],
Spanish (n=460) [9] and Dutch (n=104) [19] general population samples.
doi:10.1371/journal.pone.0038813.g002
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dures.
On the other hand, SYBRH Green labelling is sensitive to both
DNA quality and concentration [10]. The taken precautions
ensure reliable and replicable results but make the analyses more
laborious and time-consuming; (i) The housekeeping gene (beta-
actin) run prior to C4 analyses controls for the DNA quality and
concentration and it sets the samples in reference to C4 controls
(lower, equal or higher). The results of this analysis have to be
available before starting the C4 runs. (ii) To eliminate errors in
pipetting, a run includes a duplicate of every sample and control.
(iii) The fluorescence curve of every sample is individually
analyzed in contrast to the controls taking into account the
possible differences in concentrations. (iv) Degraded or old
dilutions (over 2–3 weeks of 5 ng/ml concentration) are discarded.
We are currently using sample concentrations of 10 ng/ml that are
more resistant to degradation [14]. (v) Using the concentration
range is a novel way to reduce erroneous CNV calling. However,
the standard concentration dilutions may be prone to errors.
One run lasts for approximately 90 minutes and can include up
to 44 samples. Adding 30 minutes of pipetting, a patient’s four
real-time qPCR runs take 8 hours, excluding the time for making
dilutions and analysing the results manually.
The optimization is critical and demanding for qPCR analyses,
especially with nonspecific dyes, where the specificity relies on
PCR reaction [10]. Whilst performing this, we observed that
different SYBRH Green Master Mixes might vary in efficacy in
different qPCR conditions (Table 1). This may be one of the
reasons for reported qPCR difficulties [17].
The publicly available IHWIG cell lines can be used as controls,
but not for CTins. Controls for CTins as well as for other runs can
be obtained from the authors upon request.
CTins is a mutation leading to premature stop-codon and non-
expression of C4 protein. If present, CTins causes C4A deficiency
in more than 60% of the carriers, while it has been characterized
in C4B in only three cases [9,19,21,29,30]. Thus, the assessment of
CTins can be used as a screening test for C4A deficiencies in large
materials. For individual patients, however, immunophenotyping
together with genetic analyses adds valuable information. Immu-
nophenotyping enables the detection of aberrant or non-functional
allotypes (such as A6 and B45), low complement levels due to
increased consumption or consistently low levels that may indicate
other, rare silencing mutations. The importance of different
allotypes is not known and might be a future interest.
In the patient material, CTins caused 20% of ‘‘functional’’ C4A
deficiencies and CTins was present in more than six per cents.
These figures correspond to earlier publications; three studies have
reported the frequency of CTins accounting for 10–30% of C4A
deficiencies in healthy population, but in one study, the rate was
only 1% [16,19,30,31]. CTins itself has been characterized in a
frequency between 1–6%, but has been detected only once in
Asian population [7,9,21,32].
C4A is more important in the clearance of immune complexes
and apoptotic cells, whereas C4B is involved in the defence against
microbes [7]. Accordingly, phenotypic C4A deficiencies have been
traditionally associated with susceptibility to autoimmune diseases,
whereas C4B deficiencies have shown predisposition to infections
with encapsulated bacteria, acute myocardial infarction and stroke
[1–3]. Recent studies suggests that C4A deficiency may also be
linked with increased susceptibility to infections [27,33]. The most
common C4A-B combination (2 C4A and C4B genes) was
significantly lower in patients than in reference population, further
supporting the role of abnormal C4 CNV in aberrant immune
function. However, due to the lack of background information and
heterogeneity of our patients, no conclusions can be drawn. We
are currently conducting projects that will shed light to the
potential associations between autoimmune conditions, suscepti-
bility to infections and different forms of genetic C4 deficiencies.
To our knowledge, the differences in disease associations
between C4 deficiency due to low CNV or phenotypic deficiencies
due to low CNV and CTins have not been assessed before. In a
study in hepatitis virus B non-responders, C4A deficiency was
more common in non-responders, whereas CTins in responders
[34]. The strong linkage between CTins and HLA-DRB1*13 could
explain the seemingly contradictory findings [8,9,34]. CTins was
twice but non-significantly more common in patients with
meningococcal disease, compared with controls [19]. In SLE,
the frequency of CTins was similar in cases and controls [35].
Conclusion
We describe a simple approach for determination of C4 gene
copy numbers and deficiencies due to CTins. This method exhibits
comparability with other methods and has the advantage of high
throughput and absolute quantification. The parallel use of CTins
and C4 CNV analyses increases the detection rate of C4A
deficiency, and could be used as a screening tool. In individual
patient cases, qPCR combined with immunophenotyping provides
information of the personalized C4 status in relation to gene
deletion, mutation, presence of non-functional allotypes or
increased C4 consumption and is useful in the assessment of
immune deficiencies.
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